Myomo, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYO research report →
Range $1.1 – $1.1
Price Chart
About the company
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments.
- CEO
- Paul R. Gudonis
- IPO
- 2017
- Employees
- 195
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on MYO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $32.52M
- P/E
- -2.36
- Fwd P/E
- 4.05
- PEG
- 0.10
- P/S
- 0.73
- P/B
- 13.07
- EV/EBITDA
- -4.09
- Div Yield
- 0.00%
- Gross Margin
- 70.15%
- Op Margin
- -21.78%
- Net Margin
- -33.14%
- ROE
- -208.07%
- ROIC
- -41.02%
Latest fiscal year · YoY change
- Revenue
- $40.93M+25.7%
- Gross Profit
- $26.89M+16.0%
- Op Income
- $-14,401,847
- Net Income
- $-15,573,884-151.9%
- EPS
- $-0.37-131.3%
- OCF Growth
- -341.1%
- FCF Growth
- -249.5%
- 52W High
- $1.89
- 52W Low
- $0.60
- 50D MA
- $1.32
- 200D MA
- $1.10
- Beta
- 1.71
- RSI (14)
- 29
- Avg Volume
- 335.51K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Myomo posted record Q3 revenue and gross margin improvement, with strong momentum in recurring referral channels and a tighter full-year outlook at the top end of prior guidance.· November 9, 2026
- Q3 revenue was a record $12.3 million, up 22% year over year, with gross margin at 71.3% and adjusted EBITDA approximately breakeven.
- Revenue from recurring patient sources rose to 54% of revenue from 33% a year ago, helped by MyoConnect and other referral channels.
- Orders hit a record 258 in the quarter, and management said more than 500 rehabilitation facilities and therapy centers have now referred potential MyoPro patients.
- The company added coverage for an additional 35 million lives through payer agreements or agreements in process, and is now enrolled with 7 state Medicaid programs.
- Full-year revenue guidance was narrowed to $46 million to $47 million, and management expects modest sequential gross margin improvement in Q4.
Third-quarter 2026 revenue was a record $12.3 million, up 22% from the prior-year period. Gross margin was 71.3%, versus 63.8% a year ago, an improvement of 750 basis points. The company recognized revenue on a record 222 MyoPro units, up 19% year over year, and posted adjusted EBITDA of approximately breakeven versus a $2.7 million loss a year ago. Operating loss improved to $1.7 million from $3.5 million, and net loss was $4.2 million, or $0.10 per share, versus $3.7 million, or $0.09 per share, last year. Cash, cash equivalents and short-term investments were $11.9 million at September 30, 2026. For 2026, management narrowed full-year revenue guidance to $46 million to $47 million from the previously raised range of $45 million to $47 million, and said gross margin should rise modestly sequentially in Q4. They also expect a modest sequential increase in operating expenses in Q4 due to one-time CCO transition costs and higher headcount for MyoConnect, while still targeting second-half cash burn of less than $2 million and less than $500 thousand in Q4.
Paul Gudonis emphasized that the quarter reflected execution across four priorities: growing recurring referrals, expanding payer access, improving operating leverage, and advancing product development and research. He highlighted MyoConnect’s expansion to more than 500 referral facilities, more than 200 new locations added in the quarter, and record orders as evidence that the commercial model is becoming more durable than direct-to-patient marketing alone. His tone was confident and long-term focused, pointing to a large untapped market in the U.S. and Germany and saying Myomo is still at only about 1% penetration of the addressable market.
David Henry led with the quarter’s financial performance: $12.3 million of revenue, 71.3% gross margin, and adjusted EBITDA near breakeven. He attributed the margin improvement to higher ASP, material cost reductions, and better fixed-cost absorption, while noting operating expenses increased just 6% year over year to $10.5 million. He also cited $11.9 million of cash, cash equivalents and short-term investments at quarter-end, $1.3 million of operating cash use in the quarter, and an improved cash burn of $1.5 million versus $2.2 million in the prior quarter. On outlook, he said full-year revenue guidance was narrowed to $46 million to $47 million, Q4 gross margin should improve modestly, and second-half cash burn should remain below $2 million.
Analysts focused on the sharp increase in recurring referral activity, the softer-than-usual Q3 pipeline adds, and whether MyoConnect would change the way investors should model the business. Management said the lower Q3 pipeline adds were partly seasonal and partly due to temporary staffing and lead-generation inefficiencies, but October direct-billing pipeline adds were about 30% above the Q3 monthly average after fixes. They also said MyoConnect referrals tend to produce better-qualified patients and materially higher conversion than direct-to-consumer leads, with one executive saying the program is roughly 10x better than direct-to-patient advertising at turning pipeline adds into revenue. Questions also covered reimbursement, pricing, and 2027; management said Medicare Part B reimbursement remains in place, in-network contracts improve authorization rates, pricing is largely dictated by CMS and payer benchmarks, and they are still planning for 2027 rather than giving guidance.
The call showed multiple reinforcing positives: record revenue, record orders, and a materially better gross margin profile. Management believes the shift toward recurring referral sources, expanding payer contracts, and better operating leverage can support a more durable and profitable business model.
The company is still not profitable on a net basis, cash remains limited at $11.9 million, and management is counting on continued execution to keep cash burn low. Pipeline adds were softer in Q3, direct-to-consumer lead efficiency was described as uneven, and Q4 will carry higher expenses from the commercial transition and MyoConnect buildout.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.5%
- Shares Outstanding
- 40.10M
- Float Shares
- 35.91M
of shares held by institutions
81 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rosalind Advisors, Inc. | 3.92M | ▲ 280.00K |
| Vanguard Capital Management LLC | 1.64M | 0 |
| Vanguard Group Inc | 1.56M | ▲ 71.53K |
| Clearstead Advisors, LLC | 425.60K | ▼ 9 |
| Two Sigma Investments, LP | 388.11K | ▲ 388.11K |
| Jane Street Group, LLC | 380.80K | ▼ 215.55K |
| Geode Capital Management, LLC | 350.49K | ▲ 6.07K |
| Morgan Stanley | 330.94K | ▲ 324.32K |
| Palumbo Wealth Management LLC | 278.35K | ▼ 21.42K |
| Gsa Capital Partners Llp | 252.66K | ▼ 19.21K |
| Millennium Management LLC | 247.38K | ▼ 23.91K |
| Vanguard Fiduciary Trust Co | 246.14K | ▲ 38.46K |
Held by 23 ETFs
Biggest fund positions in MYO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 13, 26 | Kovelman Harry | other | 32,500 |
| Sep 11, 26 | Kovelman Harry | sell | 15,844 |
| Oct 13, 26 | HENRY DAVID A | other | 51,250 |
| Oct 13, 26 | GUDONIS PAUL R | other | 71,250 |
| Oct 9, 26 | HENRY DAVID A | other | 6,272 |
| Oct 12, 26 | HENRY DAVID A | other | 3,133 |
| Oct 9, 26 | GUDONIS PAUL R | other | 8,363 |
| Oct 12, 26 | McClure Mary-Katherine Hale | other | 275,000 |
| Oct 12, 26 | McClure Mary-Katherine Hale | other | 0 |
| Sep 11, 26 | Kovelman Harry | sell | 15,488 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MYO coverage
Recent articles, reports, and earnings notes.
No research on MYO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYO report →Myomo (MYO) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Nov 12
What Myomo (MYO) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Myomo, Inc. (MYO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Myomo, Inc. (MYO) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 9
Myomo Reports Third Quarter 2026 Financial and Operating Results
businesswire.com · Nov 9
Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference
businesswire.com · Nov 3
Myomo to Report Third Quarter 2026 Financial Results on November 9
businesswire.com · Nov 2
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
businesswire.com · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.